# Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Source: https://onco.cc/trials/nct04437160/  
OnCo record `nct04437160` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of epirubicin, pirarubicin and cyclophosphamide in triple-negative breast cancer, run by Chinese Academy of Medical Sciences, now recruiting.

## Summary

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy is a phase 2, randomised interventional study registered as NCT04437160 by Chinese Academy of Medical Sciences, with a registry enrolment figure of 286 participants, started 2020-02-01 and due to reach its primary completion in 2026-01. Interventions recorded: Epirubicin or Pirarubicin; Cyclophosphamide. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Triple negative breast cancer: hormone receptor negative (ER \< 10% and PgR \< 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04437160
- Phase: 2
- Setting: A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Efficacy and Safety of Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Platinum-based Neoadjuvant Chemotherapy
- Sponsor: Chinese Academy of Medical Sciences
- Enrolled: 286

## Sources

- ClinicalTrials.gov NCT04437160: https://clinicaltrials.gov/study/NCT04437160

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Pirarubicin](https://onco.cc/drugs/pirarubicin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04437160.json